Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vexim goes public, but falls short of €17.5m target

This article was originally published in Clinica

Executive Summary

French kyphoplasty firm Vexim has raised €11m ($14.5m) in an initial public offering on the NYSE Alternext stock exchange in Paris. The total falls short of the €17.45m that the company said it was hoping to raise last month (, 16 April 2012), but nonetheless could be another indication that the medtech IPO market is picking up after a sluggish few years. Vexim issued 1.15 million new shares priced at €9.50 each; market capitalisation stood at €31.6m on the day of listing. The company's lead product is its SpineJack spinal implant, which is used during kyphoplasty procedures. It has been available outside the US since March 2010, but is not yet FDA approved. Earlier this year, Vexim appointed a new CEO, Vincent Gardés, as it aims to ramp up international sales of SpineJack (, 4 January 2012).





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts